Skip to main content

Table 3 Relative dose intensity (RDI) for the two treatment regimens

From: Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study

Dose Intensity Rates (DSI) in percentage

GEM Group (n = 9)

CIS/GEM Group (n = 21)

  

CIS

GEM

Cycles

Median

IQR

Cycles

Median

IQR

Median

IQR

C1

100

(91.7–100)

C1

100

(100–100)

100

(100–100)

C2

100

(95–100)

C2

100

(100–100)

100

(100–100)

C3

100

(90.9–100)

C3

100

(70–100)

100

(76.4–100)

C4

100

(86.7–100)

C4

80

(50–100)

100

(77.5–100)

C5

100

(95–100)

C5

80

(50–100)

100

(70–100)

C6

100

(88.9–100)

C6

80

(25–100)

94.1

(70–100)

   

C7

50

(0–100)

88.9

(56.3–100)

   

C8

50

(0–90)

75

(50–100)

Overall DSI

100

(91–100)

 

100

(50–100)

100

(75–100)

  1. Abbreviations: GEM gemcitabine, CIS cisplatin, IQR interquartile range, C cycles